Aug 2026· Metabolites· Vol 16, pp. 556· 0 citations· 113 references
Medicine
TL;DR
This narrative review synthesizes evidence linking inflammaging, immune-cell polarization, mitochondrial dysfunction, nutrient metabolic dyshomeostasis, and gut-derived metabolites to the pathogenesis of osteosarcopenia.
Abstract
Osteosarcopenia—defined as the coexistence of sarcopenia and osteoporosis—is increasingly recognized as a clinically important geriatric syndrome associated with falls, fractures, frailty, disability, and mortality. Beyond the simple coexistence of bone and muscle loss, emerging data suggest that osteosarcopenia may reflect systemic dysregulation of the bone–muscle–immune–metabolic network. In this narrative review, we synthesize evidence linking inflammaging, immune-cell polarization, mitochondrial dysfunction, nutrient metabolic dyshomeostasis, and gut-derived metabolites to the pathogenesis of osteosarcopenia. Multiple pathological processes—including chronic low-grade inflammation, Th17/Treg imbalance, macrophage polarization, oxidative stress, impaired mitophagy, insulin resistance, ectopic fat accumulation, and altered microbial metabolites—may converge to disrupt bone–muscle crosstalk. Notably, direct evidence from osteosarcopenic populations remains limited, and many mechanistic insights are extrapolated from osteoporosis, sarcopenia, and aging models. We further discuss current and emerging therapeutic strategies, including exercise, nutritional interventions, anti-osteoporotic agents, metabolic modulators, mitochondrial-targeted therapies, and gut-directed approaches. Longitudinal cohorts, multi-omics studies, and randomized controlled trials are urgently required to validate immunometabolic biomarkers and develop integrated interventions for osteosarcopenia.
Osteoporosis (OP) and osteoarthritis (OA) are common and highly co-occurring degenerative bone diseases in the elderly population, and their comorbidity mechanisms cannot be fully explained by traditional factors such as mechanical load, changes in bone mass, or hormonal imbalance. OP is primarily characterized by syst...
Wen-Xiong Li, Jie Liu, Jiao Li et al.· Frontiers in Immunology· 0 citations
To manage and treat osteosarcopenia, a multimodal approach, such as exercise therapy, nutritional supplementation, and pharmacotherapies, is required, and emerging drugs that positively regulate bone and muscle mass are under development and are expected to contribute to individually optimized care.
Takayoshi Sasako, M. G. Borda, Marc Sim et al.· Journal of Bone and Mineral...· 0 citations
This narrative review synthesizes current evidence supporting osteosarcopenia as an integrated musculoskeletal syndrome, with a particular focus on biomechanical loading, biochemical crosstalk, and inflammatory signaling.
Jeonghyeon Seo, Sang Hoon Hwang, J. Yoon et al.· Journal of Korean Neurosurgi...· 0 citations
Combined strategies incorporating senolytic, antiglycative, and mechanoprotective approaches—alongside lifestyle interventions—may be needed to more effectively reduce fracture risk in aged and diabetic populations.
Salvador Peñarrubia, E. Martín-Guerrero, A. Gortázar et al.· Cells· 0 citations
Key mechanistic evidence demonstrating how targeted GM interventions and structured exercise regimens may synergistically counteract muscle decline is explored, to support the development of innovative therapeutic approaches combining exercise and GM modulation to improve muscle health, functional independence, and hea...
Ana Sofia Merelim, Ângelo P. Santos, Rodrigo Zacca et al.· Sport Sciences for Health· 0 citations
Osteoporosis has long been understood, and treated, as an imbalance between osteoblastic bone formation and osteoclastic resorption. Yet many patients continue to lose bone, pointing to upstream regulators of the remodeling unit that remain poorly defined. Macrophages are developmentally continuous with osteoclasts and...
Lian Weng, Qian-Li Yuan, T. Mo et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.